Share Twitter LinkedIn Facebook Email Roy S. Herbst, MD, PhD, discusses if patient selection will change as a result of Keynote 42 Advertisement
ASCO 2025: Lung Cancer Immunotherapy Breakthroughs from the Immuno-Oncology Symposium Lung Cancer Treatment 4 Mins Read
